A Study of ONO-4538HSC in Pediatric Patients With Malignant Solid Tumors and in Patients With Epithelioid Sarcoma.

This is a multicenter, open-label, uncontrolled Phase I/II study to evaluate the efficacy, safety, and pharmacokinetics of ONO-4538HSC in pediatric patients with malignant solid tumors and in patients with epithelioid sarcoma, and to evaluate the tolerability in pediatric patients. The objective of this study is to explore the tolerability, safety, efficacy, and pharmacokinetics of ONO-4538HSC in patients with pediatric malignant solid tumors. The other objective is to exploratively investigate the efficacy and safety of ONO-4538HSC in patients with epithelioid sarcoma.

Trial Details

NCT ID
NCT07734116
Phase
PHASE1 / PHASE2
Sponsor
Ono Pharmaceutical Co., Ltd.
Status
RECRUITING
Cancer Type
Sarcoma
Interventions
  • ONO-4538HSC
Locations (sample)
  • Chiba, Chiba, Japan|35.6,140.11667
  • Kashiwa, Chiba, Japan|35.86224,139.97732
  • Fukuoka, Fukuoka, Japan|33.6,130.41667
  • Hiroshima, Hiroshima, Japan|34.4,132.45
  • Sapporo, Hokkaido, Japan|43.06667,141.35

Key Eligibility Criteria

  • \[Cohort of pediatric malignant solid tumor Tolerability evaluation part\]
  • Patients aged ≥ 12 to \< 18 years at the time of signing the informed consent form (ICF)
  • Patients with radically/curatively unresectable advanced or metastatic solid tumor who are refractory to or intolerant to standard treatment or for…
  • Patients with ECOG PS of 0 to 1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Sarcoma Trials on Trialify →